These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 31751428)

  • 1. Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
    Meriki HD; Tufon KA; Anong DN; Atanga PN; Anyangwe IA; Cho-Ngwa F; Nkuo-Akenji T
    PLoS One; 2019; 14(11):e0225575. PubMed ID: 31751428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon.
    Fokam J; Takou D; Teto G; Nforbih SE; Kome OP; Santoro MM; Ngoufack ES; Eyongetah M; Palmer D; Fokunang ET; Fokunang CN; Colizzi V; Perno CF; Ndjolo A
    PLoS One; 2020; 15(7):e0235958. PubMed ID: 32692778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
    Yendewa GA; Sahr F; Lakoh S; Ruiz M; Patiño L; Tabernilla A; Deen GF; Sesay M; Salata RA; Poveda E
    J Antimicrob Chemother; 2019 Jul; 74(7):2024-2029. PubMed ID: 30989237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E
    Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applying Next-Generation Sequencing to Track HIV-1 Drug Resistance Mutations Circulating in Portugal.
    Pimentel V; Pingarilho M; Sebastião CS; Miranda M; Gonçalves F; Cabanas J; Costa I; Diogo I; Fernandes S; Costa O; Corte-Real R; Martins MRO; Seabra SG; Abecasis AB; Gomes P
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
    Deletsu SD; Maina EK; Quaye O; Ampofo WK; Awandare GA; Bonney EY
    Medicine (Baltimore); 2020 Feb; 99(7):e18777. PubMed ID: 32049783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic HIV-1 genetic recombination and genotypic drug resistance among treatment-experienced adults in northern Ghana.
    Nii-Trebi NI; Brandful JAM; Ibe S; Sugiura W; Barnor JS; Bampoh PO; Yamaoka S; Matano T; Yoshimura K; Ishikawa K; Ampofo WK
    J Med Microbiol; 2017 Nov; 66(11):1663-1672. PubMed ID: 29068286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam.
    Bwire GM; Aiko BG; Mosha IH; Kilapilo MS; Mangara A; Kazonda P; Swai JP; Swalehe O; Jordan MR; Vercauteren J; Sando D; Temba D; Shao A; Mauka W; Decouttere C; Vandaele N; Sangeda RZ; Killewo J; Vandamme AM
    Sci Rep; 2023 Nov; 13(1):20493. PubMed ID: 37993493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.
    Elmi Abar A; Jlizi A; Darar HY; Kacem MA; Slim A
    Diagn Pathol; 2012 Oct; 7():138. PubMed ID: 23044036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
    Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
    J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study.
    Karade SK; Kulkarni SS; Ghate MV; Patil AA; Londhe R; Salvi SP; Kadam DB; Joshi RK; Rewari BB; Gangakhedkar RR
    PLoS One; 2017; 12(8):e0181889. PubMed ID: 28763465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of archived drug resistance mutations in HIV-1 DNA among vertically infected adolescents under antiretroviral treatment in Cameroon: Findings during the COVID-19 pandemic.
    Ka'e AC; Fokam J; Togna Pabo WLR; Nanfack A; Ngoufack Jagni Semengue E; Bouba Y; Nka AD; Tetang S; Beloumou G; Takou D; Chenwi C; Tommo Tchouaket MC; Abba A; Djupsa S; Sosso SM; Pamen NB; Otshudiema JO; Boum Y; Colizzi V; Ndjolo A; Perno CF; Ceccherini-Silberstein F; Santoro MM
    HIV Med; 2023 Jun; 24(6):691-702. PubMed ID: 36717222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.
    Orrell C; Walensky RP; Losina E; Pitt J; Freedberg KA; Wood R
    Antivir Ther; 2009; 14(4):523-31. PubMed ID: 19578237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.
    Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M
    J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals.
    Bokharaei-Salim F; Esghaei M; Khanaliha K; Kalantari S; Marjani A; Fakhim A; Keyvani H
    PLoS One; 2020; 15(3):e0229275. PubMed ID: 32119691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
    Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
    PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.